1 minute reading time (35 words)

Oral CGRP Drug Bests Placebo for Migraine Prevention

Atogepant, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention, led to fewer monthly migraine days in episodic monthly migraine patients, results of a phase IIb/III trial showed here. 

Related Posts

The AAPM Annual Meeting offers education and networking opportunities for all members of the pain care team.

Learn More